Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
[Advances in Oncology 2019].
Vernadou A, Ferahta N, Mederos N, Ferraro D, Dischl-Antonioni I, Diciolla A, Liapi A, Mosimann V, Latifyan S, Aedo-Lopez V, Berthold D, Digklia A, Michielin O, Montemurro M, Wagner AD, Zaman K, Peters S, Stravodimou A, Sarivalasis A. Vernadou A, et al. Among authors: latifyan s. Rev Med Suisse. 2020 Jan 15;16(676-7):72-77. Rev Med Suisse. 2020. PMID: 31961089 Review. French.
[Oncology, what's new in 2018].
Latifyan S, Kakourou A, Ozdemir B, Zaman K, Vernadou A, Berthold D, Abdelhamid K, Bouchaab H, Peters S, Montemurro M, Aedo V, Michielin O, Zimmermann S, Stravodimou A. Latifyan S, et al. Rev Med Suisse. 2019 Jan 9;15(N° 632-633):78-81. Rev Med Suisse. 2019. PMID: 30629376 French.
[Locally advanced and metastatic melanoma : novelties].
Huber A, Latifyan S, Nikolopoulou A, Homicsko K, Berthod G, Michielin O, Özdemir BC. Huber A, et al. Among authors: latifyan s. Rev Med Suisse. 2020 May 27;16(695):1092-1097. Rev Med Suisse. 2020. PMID: 32462837 Review. French.
Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany.
Ressler JM, Karasek M, Koch L, Silmbrod R, Mangana J, Latifyan S, Aedo-Lopez V, Kehrer H, Weihsengruber F, Koelblinger P, Posch C, Kofler J, Michielin O, Richtig E, Hafner C, Hoeller C. Ressler JM, et al. Among authors: latifyan s. J Immunother Cancer. 2021 Feb;9(2):e001701. doi: 10.1136/jitc-2020-001701. J Immunother Cancer. 2021. PMID: 33608376 Free PMC article.
Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy.
Ghisoni E, Wicky A, Bouchaab H, Imbimbo M, Delyon J, Gautron Moura B, Gérard CL, Latifyan S, Özdemir BC, Caikovski M, Pradervand S, Tavazzi E, Gatta R, Marandino L, Valabrega G, Aglietta M, Obeid M, Homicsko K, Mederos Alfonso NN, Zimmermann S, Coukos G, Peters S, Cuendet MA, Di Maio M, Michielin O. Ghisoni E, et al. Among authors: latifyan s. Eur J Cancer. 2021 May;149:153-164. doi: 10.1016/j.ejca.2021.03.010. Epub 2021 Apr 14. Eur J Cancer. 2021. PMID: 33865201 Free article.
[Immunotherapy for bladder cancer in 2021].
Cisarovsky C, Latifyan S, Perrinjaquet C, Berthold D, Orcurto A. Cisarovsky C, et al. Among authors: latifyan s. Rev Med Suisse. 2021 May 19;17(739):974-977. Rev Med Suisse. 2021. PMID: 34009756 French.
68Ga-DOTATOC PET/CT to detect immune checkpoint inhibitor-related myocarditis.
Boughdad S, Latifyan S, Fenwick C, Bouchaab H, Suffiotti M, Moslehi JJ, Salem JE, Schaefer N, Nicod-Lalonde M, Costes J, Perreau M, Michielin O, Peters S, Prior JO, Obeid M. Boughdad S, et al. Among authors: latifyan s. J Immunother Cancer. 2021 Oct;9(10):e003594. doi: 10.1136/jitc-2021-003594. J Immunother Cancer. 2021. PMID: 34686542 Free PMC article.
[2021 Oncology update].
Meyer ML, Chrysou K, Stamatiou A, Gilabert M, Herrera Gomez RG, Latifyan S, Masmoudi S, Mederos N, Perrinjaquet C, Berthold D, Bouchaab H, Cristina V, Digklia A, Michielin O, Orcurto A, Sarivalasis A, Stravodimou A, Wagner AD, Zaman K, Peters S, Jankovic J. Meyer ML, et al. Among authors: latifyan s. Rev Med Suisse. 2022 Feb 2;18(767):182-186. doi: 10.53738/REVMED.2022.18.767.182. Rev Med Suisse. 2022. PMID: 35107893 French.
Systematic comparison with autoimmune liver disease identifies specific histological features of immune checkpoint inhibitor-related adverse events.
Coukos A, Vionnet J, Obeid M, Bouchaab H, Peters S, Latifyan S, Wicky A, Michielin O, Chtioui H, Moradpour D, Fasquelle F, Sempoux C, Fraga M. Coukos A, et al. Among authors: latifyan s. J Immunother Cancer. 2022 Oct;10(10):e005635. doi: 10.1136/jitc-2022-005635. J Immunother Cancer. 2022. PMID: 36283734 Free PMC article.
32 results